Taro Yamashita

Diabetes attenuates weight reduction‐mediated liver fibrosis regression in persons with morbid obesity

ABSTRACT Aims Weight loss by laparoscopic sleeve gastrectomy (LSG) compared to medical weight loss (low‐calorie diet: LCD) ameliorates diabetes and metabolic dysfunction‐associated steatotic liver disease (MASLD). We aimed to evaluate changes in liver pathology 1‐year after LSG and their associations with metabolic fac...

Abstract A088: EphA2 Proteolytic Fragment Links Early Detection, IPMN Progression, and Therapeutic Resistance in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal because most patients are diagnosed after curative intervention is no longer feasible and resistance to systemic therapy is common. Intraductal papillary mucinous neoplasms (IPMNs) are important PDAC precursor lesions, but serum biomarkers for early PDAC d...

Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study

This study aimed to elucidate how sodium-glucose cotransporter 2 (SGLT2) inhibitors and sulfonylureas differentially modulate hepatic metabolism in persons with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). In this 48-week randomized, open-label, parallel-group trial, Japan...

Tofogliflozin alters amino acid metabolism in gut microbiota linked to hepatic transcriptomic signatures in MASLD.